Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial

被引：0
|
作者：
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Yin, Ming
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
Hauser, Stephen
机构：
来源：
NEUROLOGY | 2011年 / 76卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A545 / A545
页数：1
相关论文
共 50 条
  • [31] Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial
    Metz, L. M.
    Li, D.
    Traboulsee, A.
    Myles, M. L.
    Duquette, P.
    Godin, J.
    Constantin, M.
    Yong, V. W.
    MULTIPLE SCLEROSIS, 2009, 15 (10): : 1183 - 1194
  • [32] Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: Preliminary findings of a randomized, placebo-controlled trial
    Shaygannejad, Vahid
    Janghorbani, Mohsen
    Savoj, Mohammad Reza
    Ashtari, Fereshteh
    NEUROLOGICAL RESEARCH, 2010, 32 (09) : 981 - 985
  • [33] Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions
    Huntemann, Niklas
    Mueller, Marc
    Masanneck, Lars
    Baumgart, Romy
    Axhausen, Franziska
    Wolff, Stephanie
    Kutsojannis, Bela
    Koelsche, Tristan
    Korsen, Melanie
    Pfeuffer, Steffen
    Meuth, Sven
    Pawlitzki, Marc
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 90 - 91
  • [34] Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial
    Voskuhl, Rhonda R.
    Wang, HeJing
    Wu, T. C. Jackson
    Sicotte, Nancy L.
    Nakamura, Kunio
    Kurth, Florian
    Itoh, Noriko
    Bardens, Jenny
    Bernard, Jacqueline T.
    Corboy, John R.
    Cross, Anne H.
    Dhib-Jalbut, Suhayl
    Ford, Corey C.
    Frohman, Elliot M.
    Giesser, Barbara
    Jacobs, Dina
    Kasper, Lloyd H.
    Lynch, Sharon
    Parry, Gareth
    Racke, Michael K.
    Reder, Anthony T.
    Rose, John
    Wingerchuk, Dean M.
    MacKenzie-Graham, Allan J.
    Arnold, Douglas L.
    Tseng, Chi Hong
    Elashoff, Robert
    LANCET NEUROLOGY, 2016, 15 (01): : 35 - 46
  • [35] Acyclovir treatment of relapsing-remitting multiple sclerosis - A randomized, placebo-controlled, double-blind study
    Lycke, J
    Svennerholm, B
    Hjelmquist, E
    Frisen, L
    Badr, G
    Andersson, M
    Vahlne, A
    Andersen, O
    JOURNAL OF NEUROLOGY, 1996, 243 (03) : 214 - 224
  • [36] Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, phase II trial (DreaMS)
    Zipp, F.
    Vollmer, T. L.
    Selmaj, K. W.
    Bar-Or, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 199 - 199
  • [37] Safety of cladribine tablets in the treatment of relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S128 - S128
  • [38] Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
    Johnson, KP
    Brooks, BR
    Cohen, JA
    Ford, CC
    Goldstein, J
    Lisak, RP
    Myers, LW
    Panitch, HS
    Rose, JW
    Schiffer, RB
    Vollmer, T
    Weiner, LP
    Wolinsky, JS
    NEUROLOGY, 2001, 57 (12) : S16 - S24
  • [39] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
    Paty, DW
    Li, DKB
    NEUROLOGY, 2001, 57 (12) : S10 - S15
  • [40] Baseline Characteristics of Patients in the DEFINE Trial: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study of BG-12 in Relapsing-Remitting Multiple Sclerosis
    Gold, Ralf
    Arnold, Douglas
    Kappos, Ludwig
    Bar-Or, Amit
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Yang, Minhua
    Dawson, Katherine
    NEUROLOGY, 2010, 74 (09) : A546 - A547
12345